AZN logo

AstraZeneca (AZN) EBITDA

Annual EBITDA

$17.12 B
+$3.70 B+27.56%

December 1, 2024

Summary

Performance

1-Year Change

+27.56%

3-Year Change

+234.85%

5-Year Change

+155.08%

15-Year Change

+158.51%

AZN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

99.44%
AZN annual EBITDA is higher than 99.44% of companies in Healthcare sector

High & Low

All-time High

$17.12 B
AZN annual EBITDA is currently at an all-time high

3-Year Low

$5.11 B
AZN annual EBITDA is currently +234.85% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2024
AZN previous annual earnings announcement was published on Dec 1, 2024

Next Annual Earnings Report Date

N/A
AZN next annual earnings announcement has not yet been scheduled

OtherAZNprofitabilitymetrics:

Annual Revenue

$54.07 B
AZN annual revenue is $54.07 billion

Annual Net Income

$7.04 B
AZN annual net profit is $7.04 billion

Annual EBIT

$10.43 B
AZN annual earnings before interest & taxes is $10.43 billion

Annual EPS

$2.25
AZN annual earnings per share is $2.25

Quarterly EBITDA

$4.10 B
-$17.00 M-0.41%

September 30, 2024

Summary

Performance

3-Month Change

-0.41%

1-Year Change

+23.33%

3-Year Change

+114.2%

5-Year Change

+114.2%

AZN Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

99.58%
AZN quarterly EBITDA is higher than 99.58% of companies in Healthcare sector

High & Low

All-time High

$4.96 B
AZN quarterly EBITDA is currently -17.27% below its historical high of $4.96 billion

3-Year Low

-$324.00 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
AZN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

N/A
AZN next earnings announcement has not yet been scheduled

OtherAZNprofitabilitymetrics:

Quarterly Revenue

$13.56 B
AZN quarterly revenue is $13.56 billion

Quarterly Net Income

$1.43 B
AZN quarterly net profit is $1.43 billion

Quarterly EBIT

$2.29 B
AZN quarterly earnings before interest & taxes is $2.29 billion

Quarterly EPS

$0.46
AZN quarterly earnings per share is $0.46

TTM EBITDA

$14.87 B
+$776.00 M+5.51%

September 30, 2024

Summary

Performance

3-Month Change

+5.51%

1-Year Change

+9.11%

3-Year Change

+202.75%

5-Year Change

+202.75%

AZN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

99.49%
AZN TTM EBITDA is higher than 99.49% of companies in Healthcare sector

High & Low

All-time High

$16.48 B
AZN TTM EBITDA is currently -9.79% below its historical high of $16.48 billion

3-Year Low

$4.84 B
AZN TTM EBITDA is currently +207.25% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
AZN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

N/A
AZN next earnings announcement has not yet been scheduled

OtherAZNprofitabilitymetrics:

TTM Revenue

$51.21 B
AZN TTM revenue is $51.21 billion

TTM Net Income

$6.50 B
AZN TTM net profit is $6.50 billion

TTM EBIT

$9.64 B
AZN TTM earnings before interest & taxes is $9.64 billion

TTM EPS

$2.08
AZN TTM earnings per share is $2.08

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$17.12 B
AZN annual EBITDA is $17.12 billion

Annual Net Income

$7.04 B
AZN annual net profit is $7.04 billion

Annual Interest Expense

$1.74 B
AZN annual interest expense is $1.74 billion

Annual Income Tax

$1.65 B
AZN annual income tax is $1.65 billion

Annual D&A

$6.69 B
AZN annual depreciation & amortization is $6.69 billion

AZN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+27.6%+23.3%+9.1%
3 y3 years+234.8%+114.2%+202.8%
5 y5 years+155.1%+114.2%+202.8%

AZN EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+234.8%-8.2%+1366.0%at high+207.3%
5 y5-yearat high+234.8%-8.2%+1366.0%at high+207.3%
alltimeall timeat high+2391.9%-17.3%+184.9%-9.8%+3624.8%

AstraZeneca EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
$17.12 B(+27.6%)
-
-
Sep 2024
-
$4.10 B(-0.4%)
$14.87 B(+5.5%)
Jun 2024
-
$4.12 B(-7.8%)
$14.09 B(+2.4%)
Mar 2024
-
$4.47 B(+105.0%)
$13.77 B(+2.5%)
Dec 2023
$13.42 B(+47.7%)
$2.18 B(-34.5%)
$13.43 B(-1.4%)
Sep 2023
-
$3.33 B(-12.4%)
$13.63 B(+5.7%)
Jun 2023
-
$3.79 B(-8.1%)
$12.89 B(+17.1%)
Mar 2023
-
$4.13 B(+73.8%)
$11.02 B(+21.3%)
Dec 2022
$9.09 B(+77.7%)
$2.38 B(-8.4%)
$9.08 B(+42.3%)
Sep 2022
-
$2.60 B(+35.5%)
$6.38 B(+30.0%)
Jun 2022
-
$1.92 B(-12.9%)
$4.91 B(+1.5%)
Mar 2022
-
$2.20 B(-778.4%)
$4.84 B(-9.5%)
Dec 2021
$5.11 B(-36.8%)
-$324.00 M(-128.9%)
$5.35 B(-30.3%)
Sep 2021
-
$1.12 B(-39.1%)
$7.67 B(-10.0%)
Jun 2021
-
$1.84 B(-31.9%)
$8.53 B(-1.8%)
Mar 2021
-
$2.71 B(+35.5%)
$8.68 B(+7.4%)
Dec 2020
$8.08 B(+20.4%)
$2.00 B(+1.0%)
$8.08 B(-2.5%)
Sep 2020
-
$1.98 B(-1.1%)
$8.29 B(+6.4%)
Jun 2020
-
$2.00 B(-5.1%)
$7.79 B(+11.0%)
Mar 2020
-
$2.11 B(-4.4%)
$7.02 B(+4.6%)
Dec 2019
$6.71 B(-5.6%)
$2.20 B(+49.1%)
$6.71 B(-6.6%)
Sep 2019
-
$1.48 B(+20.3%)
$7.18 B(-0.8%)
Jun 2019
-
$1.23 B(-31.8%)
$7.25 B(-3.2%)
Mar 2019
-
$1.80 B(-32.7%)
$7.49 B(+5.3%)
Dec 2018
$7.11 B(+7.4%)
$2.68 B(+73.9%)
$7.11 B(+16.4%)
Sep 2018
-
$1.54 B(+4.6%)
$6.11 B(-4.4%)
Jun 2018
-
$1.47 B(+3.2%)
$6.39 B(-1.3%)
Mar 2018
-
$1.43 B(-14.9%)
$6.48 B(-2.3%)
Dec 2017
$6.62 B(-9.0%)
$1.68 B(-7.9%)
$6.63 B(-17.9%)
Sep 2017
-
$1.82 B(+16.9%)
$8.07 B(+2.2%)
Jun 2017
-
$1.56 B(-1.5%)
$7.90 B(+9.1%)
Mar 2017
-
$1.58 B(-49.3%)
$7.24 B(-0.5%)
Dec 2016
$7.28 B(+4.5%)
$3.12 B(+89.9%)
$7.28 B(+22.7%)
Sep 2016
-
$1.64 B(+82.6%)
$5.93 B(-1.8%)
Jun 2016
-
$899.00 M(-44.4%)
$6.04 B(-11.1%)
Mar 2016
-
$1.62 B(-8.9%)
$6.79 B(-2.5%)
Dec 2015
$6.96 B(+26.8%)
$1.77 B(+1.5%)
$6.96 B(+18.2%)
Sep 2015
-
$1.75 B(+5.9%)
$5.89 B(+6.1%)
Jun 2015
-
$1.65 B(-7.7%)
$5.55 B(-2.9%)
Mar 2015
-
$1.79 B(+155.1%)
$5.71 B(+4.1%)
Dec 2014
$5.49 B(-34.2%)
$701.00 M(-50.2%)
$5.49 B(-19.4%)
Sep 2014
-
$1.41 B(-22.5%)
$6.81 B(-9.3%)
Jun 2014
-
$1.82 B(+16.3%)
$7.51 B(-4.2%)
Mar 2014
-
$1.56 B(-22.8%)
$7.84 B(-6.1%)
Dec 2013
$8.34 B(-21.9%)
$2.02 B(-4.0%)
$8.35 B(-7.7%)
Sep 2013
-
$2.11 B(-1.8%)
$9.04 B(-8.1%)
Jun 2013
-
$2.15 B(+3.7%)
$9.84 B(-2.4%)
Mar 2013
-
$2.07 B(-23.8%)
$10.09 B(-5.6%)
Dec 2012
$10.68 B(-30.6%)
$2.72 B(-6.6%)
$10.68 B(-0.3%)
Sep 2012
-
$2.91 B(+21.8%)
$10.72 B(-16.0%)
Jun 2012
-
$2.39 B(-10.4%)
$12.77 B(-8.7%)
Mar 2012
-
$2.67 B(-3.2%)
$13.99 B(-9.1%)
Dec 2011
$15.39 B(+4.4%)
$2.75 B(-44.5%)
$15.39 B(-6.6%)
Sep 2011
-
$4.96 B(+37.3%)
$16.48 B(+12.5%)
Jun 2011
-
$3.61 B(-11.1%)
$14.65 B(+0.1%)
Mar 2011
-
$4.06 B(+5.6%)
$14.63 B(-0.8%)
Dec 2010
$14.74 B(+5.7%)
$3.85 B(+22.9%)
$14.75 B(+5.4%)
Sep 2010
-
$3.13 B(-12.8%)
$13.98 B(-4.5%)
Jun 2010
-
$3.59 B(-14.0%)
$14.64 B(+1.3%)
Mar 2010
-
$4.18 B(+35.4%)
$14.46 B(+3.7%)
Dec 2009
$13.95 B(+10.5%)
$3.08 B(-18.6%)
$13.95 B(+0.4%)
Sep 2009
-
$3.79 B(+11.2%)
$13.90 B(+3.8%)
Jun 2009
-
$3.41 B(-6.9%)
$13.39 B(+2.5%)
Mar 2009
-
$3.66 B(+20.6%)
$13.06 B(+3.5%)
Dec 2008
$12.62 B
$3.04 B(-7.6%)
$12.62 B(+11.1%)
DateAnnualQuarterlyTTM
Sep 2008
-
$3.29 B(+6.8%)
$11.36 B(+4.4%)
Jun 2008
-
$3.08 B(-4.3%)
$10.88 B(+4.8%)
Mar 2008
-
$3.22 B(+80.9%)
$10.38 B(+4.3%)
Dec 2007
$9.95 B(+4.1%)
$1.78 B(-36.6%)
$9.95 B(-0.3%)
Sep 2007
-
$2.80 B(+8.6%)
$9.98 B(+1.5%)
Jun 2007
-
$2.58 B(-7.4%)
$9.83 B(-2.5%)
Mar 2007
-
$2.79 B(+54.0%)
$10.09 B(+5.5%)
Dec 2006
$9.56 B(+22.1%)
$1.81 B(-31.9%)
$9.56 B(+2.8%)
Sep 2006
-
$2.66 B(-6.4%)
$9.30 B(+2.6%)
Jun 2006
-
$2.84 B(+25.6%)
$9.06 B(+10.4%)
Mar 2006
-
$2.26 B(+46.1%)
$8.21 B(+4.8%)
Dec 2005
$7.83 B(+34.6%)
$1.55 B(-36.1%)
$7.83 B(-1.2%)
Sep 2005
-
$2.42 B(+21.9%)
$7.93 B(+13.7%)
Jun 2005
-
$1.98 B(+5.5%)
$6.97 B(+9.9%)
Mar 2005
-
$1.88 B(+14.5%)
$6.34 B(+8.5%)
Dec 2004
$5.82 B(+9.7%)
$1.64 B(+12.3%)
$5.85 B(+10.9%)
Sep 2004
-
$1.46 B(+8.0%)
$5.27 B(-2.4%)
Jun 2004
-
$1.35 B(-2.2%)
$5.40 B(+5.6%)
Mar 2004
-
$1.39 B(+29.9%)
$5.12 B(-3.4%)
Dec 2003
$5.30 B(+6.7%)
$1.07 B(-33.1%)
$5.30 B(+1.9%)
Sep 2003
-
$1.59 B(+48.9%)
$5.20 B(+8.7%)
Jun 2003
-
$1.07 B(-31.7%)
$4.78 B(-4.5%)
Mar 2003
-
$1.57 B(+61.8%)
$5.01 B(+0.9%)
Dec 2002
$4.97 B(-1.0%)
$968.80 M(-17.7%)
$4.97 B(-6.6%)
Sep 2002
-
$1.18 B(-9.2%)
$5.31 B(-0.9%)
Jun 2002
-
$1.30 B(-15.0%)
$5.36 B(+2.7%)
Mar 2002
-
$1.52 B(+15.7%)
$5.22 B(+4.4%)
Dec 2001
$5.02 B(+2.1%)
$1.32 B(+7.6%)
$5.00 B(+0.5%)
Sep 2001
-
$1.22 B(+6.2%)
$4.97 B(+0.7%)
Jun 2001
-
$1.15 B(-11.5%)
$4.93 B(-1.7%)
Mar 2001
-
$1.30 B(+0.9%)
$5.02 B(+2.2%)
Dec 2000
$4.91 B(+9.2%)
$1.29 B(+8.7%)
$4.91 B(+11.3%)
Sep 2000
-
$1.19 B(-4.3%)
$4.41 B(+0.4%)
Jun 2000
-
$1.24 B(+3.9%)
$4.39 B(-0.7%)
Mar 2000
-
$1.19 B(+50.7%)
$4.42 B(-42.9%)
Dec 1999
$4.50 B(+38.5%)
$792.00 M(-32.2%)
$7.75 B(+264.3%)
Sep 1999
-
$1.17 B(-7.9%)
$2.13 B(-35.3%)
Jun 1999
-
$1.27 B(-71.9%)
$3.29 B(+13.8%)
Mar 1999
-
$4.52 B(-193.6%)
$2.89 B(+268.0%)
Dec 1998
$3.25 B(+44.7%)
-$4.83 B(-307.3%)
$785.10 M(-34.9%)
Sep 1998
-
$2.33 B(+168.1%)
$1.21 B(+23.7%)
Jun 1998
-
$869.00 M(-64.1%)
$975.55 M(-59.2%)
Mar 1998
-
$2.42 B(-154.8%)
$2.39 B(+5.9%)
Dec 1997
$2.24 B(+4.4%)
-$4.41 B(-310.1%)
$2.26 B(-40.9%)
Sep 1997
-
$2.10 B(-8.1%)
$3.82 B(-5.3%)
Jun 1997
-
$2.28 B(0.0%)
$4.03 B(+0.1%)
Mar 1997
-
$2.28 B(-180.2%)
$4.03 B(+0.1%)
Dec 1996
$2.15 B(+59.1%)
-$2.85 B(-223.1%)
$4.02 B(+89.9%)
Sep 1996
-
$2.31 B(+1.5%)
$2.12 B(+21.8%)
Jun 1996
-
$2.28 B(0.0%)
$1.74 B(-1184.3%)
Mar 1996
-
$2.28 B(-147.9%)
-$160.41 M(-62.0%)
Dec 1995
$1.35 B(-8.5%)
-$4.75 B(-345.6%)
-$421.81 M(-240.2%)
Sep 1995
-
$1.94 B(+411.0%)
$300.94 M(+153.4%)
Jun 1995
-
$378.70 M(-81.2%)
$118.74 M(-92.5%)
Mar 1995
-
$2.02 B(-150.1%)
$1.58 B(+12.9%)
Dec 1994
$1.48 B(+6.0%)
-$4.03 B(-329.9%)
$1.40 B(-8.8%)
Sep 1994
-
$1.75 B(-4.6%)
$1.53 B(+16.4%)
Jun 1994
-
$1.84 B(0.0%)
$1.32 B(+7.2%)
Mar 1994
-
$1.84 B(-147.2%)
$1.23 B(+7.8%)
Dec 1993
$1.39 B(+102.8%)
-$3.90 B(-353.4%)
$1.14 B(-77.4%)
Sep 1993
-
$1.54 B(-12.1%)
$5.03 B(+44.0%)
Jun 1993
-
$1.75 B(0.0%)
$3.50 B(+100.0%)
Mar 1993
-
$1.75 B
$1.75 B
Dec 1992
$687.06 M(-59.1%)
-
-
Dec 1991
$1.68 B(+22.2%)
-
-
Dec 1990
$1.37 B
-
-

FAQ

  • What is AstraZeneca annual EBITDA?
  • What is the all time high annual EBITDA for AstraZeneca?
  • What is AstraZeneca annual EBITDA year-on-year change?
  • What is AstraZeneca quarterly EBITDA?
  • What is the all time high quarterly EBITDA for AstraZeneca?
  • What is AstraZeneca quarterly EBITDA year-on-year change?
  • What is AstraZeneca TTM EBITDA?
  • What is the all time high TTM EBITDA for AstraZeneca?
  • What is AstraZeneca TTM EBITDA year-on-year change?

What is AstraZeneca annual EBITDA?

The current annual EBITDA of AZN is $17.12 B

What is the all time high annual EBITDA for AstraZeneca?

AstraZeneca all-time high annual EBITDA is $17.12 B

What is AstraZeneca annual EBITDA year-on-year change?

Over the past year, AZN annual EBITDA has changed by +$3.70 B (+27.56%)

What is AstraZeneca quarterly EBITDA?

The current quarterly EBITDA of AZN is $4.10 B

What is the all time high quarterly EBITDA for AstraZeneca?

AstraZeneca all-time high quarterly EBITDA is $4.96 B

What is AstraZeneca quarterly EBITDA year-on-year change?

Over the past year, AZN quarterly EBITDA has changed by +$776.00 M (+23.33%)

What is AstraZeneca TTM EBITDA?

The current TTM EBITDA of AZN is $14.87 B

What is the all time high TTM EBITDA for AstraZeneca?

AstraZeneca all-time high TTM EBITDA is $16.48 B

What is AstraZeneca TTM EBITDA year-on-year change?

Over the past year, AZN TTM EBITDA has changed by +$1.24 B (+9.11%)